Prof. Dr. med. Katja Zirlik

Specialist in hematology FMHSpecialist in Medical Oncology FMH

Core competencies

Treatment of tumor and blood diseases; FMH General Internal Medicine and Hematology; Hematology and Oncology (D)

Highly specialized in the treatment of hematological diseases

Career

Since 2022
Founding partner and medical staff member Tumor & BreastCenter Eastern Switzerland

2016-dato
Oncology consultation/consultation service at Schiers Hospital

2016-2022
Medical activity as an internist in private practice with a focus on hematology and internal oncology at the Tumor Center ZeTuP Chur

2011-2016
Senior Physician, Department of Hematology, Oncology and Stem Cell Transplantation, Medical University of Freiburg (Prof. Dr. Dr. h.c. R. Mertelsmann, since 2012 Prof. Dr. J. Duyster)

11/2012
Specialist in hematology and oncology

12/2010
Habilitation in internal medicine with the title "Influencing survival-relevant anti-apoptotic signaling pathways as a therapeutic approach to chronic lymphocytic leukemia", Medical Faculty of the University of Freiburg

11/2008
Specialist in internal medicine

2005-2011
Research Associate / Ward Physician, Department of Hematology and Oncology and Stem Cell Transplantation, University Medical Center Freiburg i.Br. (Prof. Dr. Dr. h.c. R. Mertelsmann)

2003-2005
Postdoctoral Fellow, (Prof. Dr. John G. Gribben, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA), Research Fellowship of the Deutsche
Cancer Aid, research focus: Immunotherapy of chronic lymphocytic leukemia
Show more

Teaching activity

2001-2016
Teaching at the Faculty of Medicine, Albert-Ludwigs-University, Freiburg im Breisgau: main lecture "Internal Medicine", lecture "Molecular Biology in Internal Medicine", seminar Internal Medicine "Solid Tumors", course "Clinical Chemistry and Hematology", seminar Internal Medicine "Hematology", course "Internal Medicine"

Since 2016 Course
"Internal Medicine", bed-side teaching for students in higher semesters

Memberships

  • American Society of Hematology
  • German Society for Hematology and Oncology
  • Working Group for Internal Oncology
  • Swiss Group for Clinical Cancer Research (SAKK)
  • Swiss Society for Medical Oncology

Courses & Certificates

  • November 2007 Course for investigator including GCP training
  • November 2012 Course for Coordinating Investigators
  • September 2015 GCP Refresher
  • March 2019 GCP Certificate (GCP-E6(R2) 2016)
  • March 2020 Course for genetic counseling in oncology, SAKK

Publications

Zirlik K, Veelken H.

Idelalisib.

Recent Results Cancer Res. 2018;212:243-264.

 

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018 Jan 2;128(1):427-445.

 

Zirlik K, Duyster J.

Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat. 2018;41(4):166-171.

 

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Eur J Haematol. 2018 Jul 24.

 

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia. 2018 Aug;32(8):1869-1873.

 

Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K.

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia. Haematologica. 2018 Jan;103(1):136-147.

 

Zirlik K, Duyster J

Combination of Antiangiogenics and Other Targeted Therapies

Springer International Publishing AG 2017

  1. Marmé (ed.), Tumor Angiogenesis

 

Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.

PLoS One. 2016 Dec 30;11(12).
Show more